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a  b  s  t  r  a  c  t
Brain  region-speciﬁc  expression  of proteolytic  enzymes  can  control  the  biological  activity  of endoge-
nous  neuropeptides  and  has  recently  been  targeted  for  the  development  of  novel  drugs,  for  neuropathic
pain,  cancer,  and  Parkinson’s  disease.  Rapid  and  sensitive  analytical  methods  to  proﬁle  modulators  of
enzymatic  activity  are  important  for  ﬁnding  effective  inhibitors  with  high  therapeutic  value.
Combination  of  in  situ  enzyme  histochemistry  with  MALDI  imaging  mass  spectrometry  allowed  devel-
oping  a highly  sensitive  method  for analysis  of brain-area  speciﬁc  neuropeptide  conversion  of  synthetic
and  endogenous  neuropeptides,  and  for selection  of peptidase  inhibitors  that  differentially  target  conver-
sion  enzymes  at  speciﬁc  anatomical  sites.  Conversion  and  degradation  products  of Dynorphin  B as model
neuropeptide  and  effects  of  peptidase  inhibitors  applied  to  native  brain  tissue  sections  were  analyzed  at
different  brain  locations.  Synthetic  dynorphin  B (2 pmol)  was  found  to  be converted  to the  N-terminal
fragments  on brain  sections  whereas  fewer  C-terminal  fragments  were  detected.  N-ethylmaleimide
(NEM),  a non-selective  inhibitor  of cysteine  peptidases,  almost  completely  blocked  the  conversion  of
dynorphin  B to dynorphin  B(1–6;  Leu-Enk-Arg),  (1–9),  (2–13),  and  (7–13).  Proteinase  inhibitor  cocktail,
and  also  incubation  with  acetic acid displayed  similar  results.
Bioconversion  of synthetic  dynorphin  B  was  region-speciﬁc  producing  dynorphin  B(1–7) in the  cor-
tex  and dynorphin  B  (2–13)  in the striatum.  Enzyme  inhibitors  showed  region-  and  enzyme-speciﬁc
inhibition of  dynorphin  bioconversion.  Both  phosphoramidon  (inhibitor  of the  known  dynorphin  con-
verting  enzyme  neprilysin)  and  opiorphin  (inhibitor  of neprilysin  and  aminopeptidase  N)  blocked  cortical
bioconversion  to  dynorphin  B(1–7),  wheras  only  opiorphin  blocked  striatal  bioconversion  to dynorphin
B(2–13).
This method  may  impact  the development  of  novel  therapies  with  aim to strengthen  the  effects  of
endogenous  neuropeptides  under  pathological  conditions  such  as  chronic  pain.  Combining  histochem-
istry  and  MALDI  imaging  MS is  a powerful  and  sensitive  tool  for the  study  of inhibition  of enzyme  activity
directly  in  native  tissue  sections.
© 2016  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionIt is often desirable to screen enzyme activity in complex sample
atrices, such as tissues, as this can give biologically more relevant
ata than in vitro assays. Neuropeptides are often involved in sev-
Abbreviations: IMS, imaging mass spectrometry; DA, dopamine; PD, Parkinson’s
isease; LID, L-DOPA-induced dyskinesia; NEM, N-Ethylmaleimide; DynB, dynor-
hin B.
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eral different processes engaging different brain regions (example
opioid neuropeptides: reward, pain, movement control, etc.); thus
agonist/antagonist have often displayed unwanted side-effects as
other areas than intended are affected. For example, for opioid pep-
tides the need to alleviate pain is also associated with a risk of
developing drug dependence. Therefore, it is highly desirable to ﬁnd
region-speciﬁc targets whenever this is possible. In particular brain
enzymes often display characteristic expression patterns conﬁned
to distinct areas, for example the mouse angiotensin-converting
enzyme is strongly localized to the striatum, globus pallidus, and
substantia nigra of the basal ganglia [1]. The lateral striatum
has been shown to express high levels of prodynorphin mRNA
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Localized bioconversion in disease model and experimental set-up. (A) MALDI imaging MS  of endogenous dynorphins in experimental Parkinson’s disease (PD). The
rat  model of PD use a unilateral injection of 6-hydroxydopamine to produce a dopamine denervated striatum (to the right side in images), whereas the contralateral striatum
is  left intact. After L-DOPA-treatment some subjects develop abnormal involuntary movements that are similar to dyskinesia in PD patients. The severity of dyskinesia is
positively correlates to the levels of dynorphin neuropeptides, predominantly dynorphin B (DynB), alpha-neoendorphin (aNeo), and aNeo(2–8)(arrows). The des-tyrosinated
dynorphins were only up-regulated in the striatum, but not in other areas such as the substantia nigra (not shown) [4,5]. Modiﬁed from Hanrieder et al. [4] (B) Experimental
design  combining in situ histochemistry with MALDI imaging MS,  where the enzyme inhibitor is ﬁrst added to one side of a normal control brain section, here at the level
of  the striatum. A substrate, dynorphin B (DynB), dissolved in ammonium acetate is added to all spots on both sides of the brain section before applying the MALDI matrix.
Using  MALDI imaging MS  it is possible to detect the levels of substrate and peptide bioconversion products simultaneously, such as dynorphin B(2–13) at m/z 1408 and
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f  dynorphin B and Leu-Enk-Arg (yellow box). Corpus callosum, cc; cortex, cx; stria
eferred to the web  version of this article.)
nd dynorphin neuropeptides after the development of L-DOPA-
nduced adverse drug effects (dyskinesia) in Parkinson’s disease
2–5]. In previous studies we found that the levels of small dynor-
hins (dynorphin B and alpha-neoendorphin) in the parkinsonian
triatum and substantia nigra were positively correlated with the
everity of dyskinesia [4,5]. Although all dynorphins can bind and
ctivate kappa opioid receptors, both dynorphin B and alpha-
eoendorphin can interact with the other opiate receptors and in
articular alpha-neoendorphin displays the least selectivity [6,7].
fter release dynorphin peptides are bioconverted into shorter
euroactive fragments, sometimes targeting other receptors than
he original parent peptide. In the rat model of Parkinson’s disease,
e have previously noted that in animals with a severe degree of
otor adverse drug effects (dyskinesias) the des-tyrosination of
he dynorphin peptides dynorphin A(1–8), dynorphin B, and alpha-zyme inhibitor NEM (67 nanomol) almost completely blocked the des-tyrosination
str. (For interpretation of the references to color in this ﬁgure legend, the reader is
neoendorphin is rapidly occurring in the striatum, but not the target
structure substantia nigra (Fig. 1A) [4,5]. However, not much is
known about the bioconversion of dynorphins in vivo and therefor
dynorphin B was  selected as the model neuropeptide in the current
study [8,9].
Area-speciﬁc expression of CNS enzymes is known to modify
the biological activity of several endogenous neuropeptides [8,10]
and has recently been targeted for the development of novel drugs,
for example for use in neuropathic pain [11–13]. Unbiased, rapid,
and sensitive analytical tools to screen new drugs targeting enzy-
matic activity are important for ﬁnding drugs with high efﬁcacy
and therapeutic value.
This study focuses on establishing a fast and sensitive method
with high-throughput capacity for screening enzyme inhibitors and
their effects in different parts of the brain by combining in situ
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istochemistry with MALDI imaging mass spectrometry. Prior to
he introduction of immunohistochemistry, in situ histochemistry
ncubating a substrate often linked to a chromogen on fresh frozen
issue sections was the gold standard in pathology for the diagno-
is of many diseases, including brain lesions, myocardial infarction,
nd celiac disease [14]. MALDI mass spectrometry has frequently
een used for the detection of enzymatic activity, however to our
nowledge there are no reports of using complex matrices such as
issue sections although this would often yield more biologically
elevant information [15]. MALDI imaging MS  is a versatile tech-
ique allowing unbiased (as no labeling is required) detection of
any peptides and proteins simultaneously in the same biologi-
al tissue samples [16–18]. Here we add synthetic dynorphin B as
ur model substrate together with both general and more speciﬁc
nzyme inhibitors, and map  the peptide products in different parts
f the brain using 2,5-dihydroxybenzoic acid (DHB) as a MALDI
atrix as previously described [19,20].
. Materials and methods
.1. Animals, tissue preparation and ethical approval
Female 210–250 g Sprague-Dawley rats (Scanbur BK AB,
weden), were used in this experiment. Animals were housed
our to a cage with a 12:12 light/dark cycle with food and water
d libitum.  The experiment was approved by the Uppsala animal
thics committee (no 140/8) and conducted in accordance with
he guidelines of Swedish legislation on animal experimentation
Animal Welfare act SDS1998:56) and European Union Legisla-
ion (Convention ETS123 and Directive 86/609/EEC). The rats were
eeply anesthetized with isoﬂurane and decapitated. The brains
ere immediately removed after death (<30 s) and frozen on ﬁnely
round dry ice.
.2. MALDI imaging mass spectrometry
Rat brain sections (12 m thick) were cut on a cryostat,
ounted on indium-tin oxide (ITO)-coated slides (Bruker Dalton-
cs, Germany) and stored at −20 ◦C until use. Unless otherwise
tated, all chemicals were obtained from Sigma-Aldrich Co. (St.
ouis, MO).
It is common to minimize the risk of interfering signals dur-
ng MALDI analysis using ethanol washing; this was tested in a
rst experiment where tissue sections were washed once in 70%
nd twice in 95% ethanol (10 s and 2 times 10 s respectively) and
ompared with non-washed sections. No enhancement of signal
as detected and the following experiments were carried out
n non-washed sections. N-ethylmaleimide (NEM aminopeptidase
nhibitor) were applied using micropipette (0,2 L of 333 mM or
33 M in 150 mM ammonium acetate (AmAc; pH 7; in LC–MS
rade water) followed by dynorphin B peptide (2 pmol in 0.2 L
mAc) and let dry at room temperature for 10 min  before apply-
ng the MALDI matrix. The incubation time is thus limited to
he 5–6 min  it takes for the 0.2 L dynorphin B in AmAc to dry
ompletely and would be identical for all deposits across the exper-
ment.
In order to establish a biologically effective concentration of
peciﬁc inhibitors, six sections were microspotted as described
bove. The general inhibitor Protease Inhibitor Cocktail (PIC; Roche,
ermany, ½ tablet in 5 mL  AmAc), 10% acetic acid (HAc, in AmAc),
nd the inhibitors opiorphin (500 M in AmAc) and phosphorami-
on (100 M in AmAc)) as well as vehicle (AmAc) alone were
pplied at three positions in cortex, one in dorsal and one in ven-
ral striatum. The sections were allowed to dry before applying the
ynorphin B substrate.s 87 (2017) 20–27
For micropipetted samples, matrix solution (0,2 L of 25 mg/mL
2,5-di-hydroxybezoic acid (DHB) in 50% methanol, 40% water
(LC–MS grade), 10% 150 mM AmAc and 0,3% triﬂuoroacetic acid
(TFA) was applied twice. For imaging MS,  dynorphin B (10 M)
alone or mixed with either opiorphin (500 M) or phosphoramidon
(100 M),  was applied at a resolution of 575 m using a chemical
inkjet printer (ChIP, Shimadzu, Japan). The solutions were applied
at 50 drops per pass and 2 passes, and followed by matrix solution
(20 drops per pass, 10 passes).
FlexImaging (Bruker Daltonics) was  used to create the imaging
sequence of micropipetted matrix spots, but because of the size
and typical crystallization of DHB into ring like structures the mass
spectra were collected manually (2000 shots collected for each
spot) using a smart beam technology-equipped Ultraﬂex II (Burker
Daltonics) operating in reﬂector positive mode. For printed arrays
of DHB matrix, the size of each matrix deposit was close to the size
of the laser beam and 800 shots per spot were collected in auto-
matic mode. External calibration was  performed with a standard
peptide mix  (Peptide Standard Calibration II, Bruker Daltonics).
Baseline correction (Convex Hull) was  performed for each individ-
ual spectrum and exported as dat-ﬁles using FlexAnalysis (Bruker
Daltonics). Average mass spectra were created and analyzed in
OriginPro (OriginLab Corporation, MA). If the total ion current of
the experimental group did not differ from control group (DynB
only) then a total ion current normalization was  applied. The area
under the curve was calculated for each dynorphin peak detected
(signal-to-noise >3 and not present in control tissue without added
dynorphin B) and used for statistics analysis. F-test analysis of vari-
ance revealed unequal variance between groups and the data was
log-scaled for further analysis using ANOVA or Student’s T-test
(two-tailed, alpha 0.05, the null hypothesis was rejected at P < 0.05).
3. Results and discussion
High levels of endogenous dynorphin peptides are mainly local-
ized to the ventral striatum in the normal intact rat striatum.
In order to reliably detect dynorphin B in the ventral striatum
it was necessary to increase the laser intensity at which point
the synthetic dynorphin B saturated the detector, thus a lower
laser intensity was chosen for the rest of the study. The differ-
ence between endogenous and exogenous applied dynorphin B was
more than 4 orders of magnitude, making it impossible to visualize
the endogenous dynorphins on the same scale in the images shown
in the current study.
The concept of these experiments is to ﬁrst apply the enzyme
inhibitor to one side of normal intact brain, and then the substrate
is deposited to both sides and allowed to dry (Fig. 1B). DHB matrix
in an organic solution was applied and mass spectra were acquired
using a MS  imaging software in so-called proﬁling mode. First, a
rather general inhibitor of proteases N-ethylmaleimide (NEM), that
has been shown to inhibit dynorphin degradation in spinal cord
[21], was chosen for the investigation of dynorphin B bioconversion
at three sites in the normal intact brain; the cortex, the dorsal and
ventral striatum.
Several proteolytic fragments were detected after addition of
2 pmol dynorphin B in the absence of NEM inhibitor and compared
to a blank control. Dynorphin B(1–6; also called Leu-Enk-Arg),
(1–9), (1–12), and (7–13) were the most abundant peptide products
(Fig. 2, Supplemental Table 1). But in addition, dynorphin B (1–7;
Leu-Enk-Arg-Arg), (1–8), (1–10), and the des-tyrosinated dynor-
phin B(2–13) could easily be detected in the striatum, whereas
dynorphin B(1–5; Leu-Enk), (1–11), (4–13) and (6–13) displayed
low intensities.
NEM (67 nmol) almost completely (>90%) blocked the conver-
sion of dynorphin B to dynorphin B(1–6), (1–9), (2–13), and (7–13)
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Fig. 2. Synthetic dynorphin B is bioconverted in native tissue sections and NEM blocks this conversion. Representative spectrum show the major peptide product fragments
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Figs. 2 and 3, Supplemental Table 1; p < 0.05). In some cases the
ioconversion of dynorphin B was only partially blocked by NEM,
ndicating activity of other non-cystein enzymes (Fig. 3; p < 0.1 but
0.05). Fewer C- than N-terminal peptide products were detected
nd the effect of NEM was more pronounced in the striatum com-
ared with cortex. Lower amounts of NEM (67 pmol) only partially
locked the conversion of dynorphin B. The ion intensities of syn-
hetic dynorphin B were almost the same in the presence and
bsence of NEM, suggesting that very little dynorphin B had been
etabolized in this experiment (4% of peptide only group; Fig. 3
nd Supplemental Table 1).
Brain tissue is known to contain salts that interfere with desorp-
ion and ionization of endogenous neuropeptides. Typically, a few
rief washing steps (10 s in 70%, 95%, and 95% ethanol) are included
n order to enhance the endogenous neuropeptide signals [19]. The
thanol washes did not increase the detection of the added dynor-
hin B and its products, thus only non-washed tissue was used for
uture experiments (data not shown). Another common concern is
hat the enzyme inhibitor causes ion suppression effects and thus
roduces false positive results. No ion suppression effects could
e detected in the lower and higher molecular weight range (m/z
33 in Fig. 4; Supplemental Fig. 1). No in source fragmentation was
etected from synthetic dynorphin B placed directly on a stainless
teel target using the same acquisition method.
The combination of in situ histochemistry and MALDI imag-
ng MS  could be applied to both general inhibition of proteases
nd more speciﬁc inhibitors of peptidases. Unspeciﬁc inhibition
f enzymatic activity by lowering the pH with acetic acid was
he most effective strategy to block bioconversion of dynorphin B
Fig. 4). The majority of peptide product formation was blocked by
cetic acid (ten out of twelve fragments) and about 60% more intactcompletely blocked the bioconversion of dynorphin B (DynB) to Leu-Enk and the
onoisotopic m/z. (For interpretation of the references to color in this ﬁgure legend,
dynorphin B remained after acetic acid addition compared with
dynorphin B alone and vehicle followed by dynorphin B. The pro-
teinase inhibitor cocktail is a commercially available mix  of many
protease inhibitors, including for example aprotinin, bestatin, and
leupeptin, and blocked the bioconversion into 4 peptide products
by more than 60% and an additional 3 peptide products by about
30%.
Phosphoramidon (PA) is a metallo-endopeptidase inhibitor
known to block the enkephalinase neprilysin (also called neutral
endopeptidase, NEP; EC 3.4.24.11) in CNS. Recently, the similar
phosphoramidon-sensitive NEP-2 has proven a critical amyloid-
beta-degrading enzyme, causing plaque deposition when inhibited
[22]. In neuropathic pain, the inhibition of neprilysin is used
to increase the endogenous levels of opioids and alleviate pain
[11–13]. Neprilysin mainly cleaves between two hydrophobic
amino acids, and is known to cleave before the phenylalanine in
position 4 of dynorphin B. Indeed, PA signiﬁcantly reduced the
formation of dynorphin B(4–13) by about 30% in the cortex and
in addition blocked the formation of dynorphin B(1–10) by more
than 60% in both striatum and cortex (Fig. 4). In neuropathic pain a
novel concept targets both neprilysin and another enkephalinase:
aminopeptidase N (ANPEP or APN1, EC 3.4.11.2), that is mainly
responsible for removing the initial tyrosine that confer binding
and activation of all endogenous opioid peptides to their receptor
[11–13]. Opiorphin is a potent inhibitor of both aminopeptidase
N and neprilysin, and has been implicated for treatment of neu-
ropathic pain and cancer [11,23]. In the current study, opiorphin
inhibited the formation of 5 dynorphin peptide products, including
dynorphin B(2–13), (6–13), and (7–13) (Fig. 4).
Using a chemical ink-jet printer to apply inhibitor and substrate
it is possible to analyze a large set of tissues rapidly and using much
24 E. Bivehed et al. / Peptides 87 (2017) 20–27
Fig. 3. Bioconversion into several peptide products blocked by NEM. Average intensity was measured as area under the curve and expressed as percent of synthetic dynorphin B
(DynB)  (average ± SEM of six matrix deposits in cortex, dorsal and ventral striatum). NEM had different effect on the conversion into each fragment. The formation of fragments
(1–6),  (1–9), (2–13), and (7–13) were blocked with more than 90%, whereas other fragments revealed only a partial block, and a few showed a trend towards signiﬁcant block:
d k of c
s s wer
w
s
i
o
e
p
p
s
i
(
e
v
w
s
e
cynorphin B (1–7; 1–10; 6–13; p < 0.1). The bottom panel demonstrates how a bloc
oftware and where color intensity is reﬂecting peak height. Other molecular specie
as  repeated once with similar results. *p < 0.05; **p < 0.01; ***p < 0.001.
maller volumes (drop size 80 picoliter). In addition, this also makes
t possible to print several iterations of either analyte or buffer in
rder to increase incubation time and enabling a more complete
nzyme reaction, which has previously been shown for on-tissue
rotein trypsinization [20]. In the current study 100 fmol dynor-
hin B was applied to each spot in an array across a rat brain tissue
ection at the coronal level of striatum. On consecutive sections
nhibitors were applied together with the substrate dynorphin B
a total of 5 pmol OPI or 1 pmol PA, with 100 fmol dynorphin B in
ach spot) and MALDI imaging MS  acquired. Dynorphin B biocon-
ersion displayed three distinct patterns; the most predominant
as a homogenous bioconversion across all brain regions, howevereveral fragments were enriched in the somatosensory cortex (for
xample dynorphin B(1–7)), and dynorphin B(2–13) showed espe-
ially high intensities in the striatum (Fig. 5). Opiorphin blockedonversion into dynorphin B (2–13; 1–6) is visualized using the MALDI imaging MS
e not affected by NEM, for example the unknown peak at m/z 733. This experiment
formation of both these fragment, whereas phosphoramidon only
blocked the formation of dynorphin B(1–7).
That enzyme activity is retained in native frozen sections is
well known and that tissue preparation is important for imag-
ing mass spectrometry has been shown in several studies [24,25].
Using this knowledge it has been possible to monitor degradation
of endogenous phospholipids and proteins in a time-dependent
manner using MALDI imaging MS  [24,26]. Dynorphin bioconver-
sion has previously been shown to differ between the striatum and
substantia nigra, using either brain homogenates or microdialysis
to infuse synthetic dynorphin and analyzing the collected dynor-
phin fragments using MALDI TOF MS  [27–30]. For example, Prokai
et al. noted a very similar bioconversion pattern to our results
by incubating dynorphin A(1–8) with synaptosomes and synaptic
membranes demonstrating bioconversion into dynorphin A (2–8),
(1–6), and Leu-Enk. In addition, several groups have noted that
E. Bivehed et al. / Peptides 87 (2017) 20–27 25
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ifference in effect between cortex and striatum when individual mass spectra wer
EM  experiment. Average trace of 4 or 5 matrix deposits per treatment ± SEM.
any synthetic dynorphins are rapidly converted into their des-
yrosine form both in vivo and in vitro [30–33]. However, using
omogenates you have to have a priori knowledge of what speciﬁc
reas contain the target enzyme, whereas using MALDI imaging
S you can screen entire sections for enzymatic activity. In addi-
ion, it is possible to target multiple areas using proﬁling/imaging
S  in order to quickly assess enzyme activity levels in a high-
hroughput manner. Similarly, microdialysis studies require a large
umber of subjects and take a long time to perform compared to the
xperiment described here where hundreds of sections through a
tructure such as striatum can be obtained from one single animal.
n the other hand, the microdialysis probe placement ensures that
nly the bioconversion of dynorphin in the extracellular space is
easured, whereas the on-tissue histochemistry will reﬂect pep-
idase activity in all compartments similar to what is found using
adioimmune assays.
Metabolism of dynorphin into shorter fragments is known
o produce bioactive peptides that modulate neuronal signaling,
ometimes interacting with receptors that do not recognize therphin (OPI) and phosphoramidon (PA) displayed discrete effects that indicated a
cted (not shown). This experiment was conducted in less than a day, similar to the
parent peptides [8]. Bioconversion of this kind is not unique for
opioid peptides, but has also been observed with substance P, noci-
ceptin, and angiotensin II [10]. This has generated great interest in
the development of enzyme inhibitors for the therapeutic potential
of treatment of pain, addiction, depression, and other neurologi-
cal diseases [9,21,34,35]. It is suspected that many bioconversion
fragments have biologically important, but yet unknown functions.
Indeed, a recent study comparing results from many peptidomics
projects (using focused microwave irradiation to reduce post-
mortem degradation of proteins and peptides) shows that the
number of endogenous fragments is much larger than anticipated
and postulates that this indicate their biological importance [36].
4. ConclusionThis proof-of-concept study demonstrates that it is possible to
combine in situ histochemistry with unbiased analysis using MALDI
imaging MS  to rapidly screen the effect of enzyme inhibitors in dif-
ferent parts of the brain. This method can easily be adapted for other
26 E. Bivehed et al. / Peptides 87 (2017) 20–27
Fig. 5. Imaging MS  reveals enzyme- and region-speciﬁc inhibition. Synthetic dynorphin B (100 fmol per matrix deposit) was generally bioconverted in both striatum and
cortex  to an equal extent. However, the dynorphin B (1–7) and (2–13) fragments displayed distinct localization to the somatosensory cortex (arrows in DynB(1–7)) and
striatum (arrows in DynB(2–13), respectively. Opiorphin (OPI) effectively blocked the conversion into several fragments, including striatal dynorphin B (2–13), whereas
phosphoramidon (PA) reduced cortical dynorphin B (1–7) and showed no effect on dynorphin B(2–13). A fold of the right edge of the tissue caused a mass shift that is
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tetected as a lower signal in the DynB ion image and correspondingly an unknown 
as  washed off, revealing the underlying anatomical structures used for delineatio
efore  and after matrix removal).
urposes and used for example in ADME studies for the detection
f early signs of liver and kidney toxicity by measuring alkaline
hosphatase activity in situ [14].
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